Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[haysaw]

Comment from NAH story:

lorraine says:
March 12, 2013 at 1:01 pm
I think it would be great if this product ultimately performs as wished, but I’m disappointed that this article mostly sounds like an ad for the company and uses much of the product pitch on the company website in its content. I have read all of the scientific evidence for this anti-inflammatory. Except for one in vitro (cells in petri dish) human microglial cell study with only an n=4 in each treatment arm, all the published studies are on mice models. A mouse model does not a human treatment make most of the time. If it did, we would have cured cancer and AIDS by now because there are thousands of studies of successful treatments in murine models that did not eventuate in successful treatments in humans. The study that’s getting all the play in the media right now, and to which this article refers, is an unpublished in-house study done by the company. I don’t wish to be such a skeptic, but in my experience working for pharma and supplement companies, they sell hard on preliminary unpublished in-house data, and then many of those studies never get accepted for publication because of problems with the data (Fukothin being one that comes immediately to mind. They made bazillions by selling on preliminary in-house data that never got accepted for publication in spite of their promises that it was coming. Hardly anybody who parted with their share of those bazillions lost weight either). Until the paper shows up in publication, there’s no way of knowing if the difference in thyroid antibodies in the treatment arm was due to the anatabine or to something else confounding that result, or how powerful or weak the study design was. It’s great, though, that everyone posting here has had such amazing results with the product. There’s also a fair amount of positive commentary on Amazon about the product, but I have noticed that a large percentage of the 5 star reviews are from individuals who have never reviewed any other product. Sometimes that’s an indication that those reviews are company placements. As a physiologist working on the food/botanical side of reducing inflammation in my clients who suffer, I’d love for this product to work, and I wouldn’t care how much it cost, I’d recommend it. But the cart is before the horse right now, IMO. The biggest reason for optimism, however, is that the study authors have, in fact, been previously published in good journals. Hopefully, this upcoming data is strong.